Half-year report · HY
4886.TEDINET S100WZ8Y
Period2025-04-01 → 2025-09-30
Filed2025-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥35.3bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥64.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥32.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥2.6bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.7bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.8bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥3.3bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥5.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.4bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥2.6bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥108.8bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥103.9bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥88.3bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥36.2bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.3bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥72.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥71.6bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥64.2bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥6.6bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥7.1bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥13.7bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥16.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥6.0bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥6.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥78.49 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥179.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥90.36 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 61.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 72.7% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2025-09-30 | ¥141m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2025-09-30 | ¥99m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥15m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥42m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥870m |
| Animal Health Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.8bn |
| Animal Health Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥282m |
| Oversea Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥2.1bn |
| Oversea Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥132m |
| Pharmaceutical Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥29.3bn |
| Pharmaceutical Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥35.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥42m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥151m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥113m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥4m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥38m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥652m |
| Animal Health Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| Animal Health Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥177m |
| Pharmaceutical Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥28.6bn |
| Pharmaceutical Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥38m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥4.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 488
| Item | Context | Value | Unit |
|---|---|---|---|
| Raw materials and supplies | InterimInstant | 12498000000 | JPY |
| Other ca | Prior1YearInstant | 5423000000 | JPY |
| Other ca | InterimInstant | 6823000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -94000000 | JPY |
| Allowance for doubtful accounts ca | InterimInstant | -77000000 | JPY |
| Current assets | Prior1YearInstant | 58007000000 | JPY |
| Current assets | InterimInstant | 57825000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 18709000000 | JPY |
| Property plant and equipment | InterimInstant | 19268000000 | JPY |
| Goodwill | Prior1YearInstant | 2784000000 | JPY |
| Goodwill | InterimInstant | 2408000000 | JPY |
| Other ia | Prior1YearInstant | 7602000000 | JPY |
| Other ia | InterimInstant | 6744000000 | JPY |
| Intangible assets | Prior1YearInstant | 10386000000 | JPY |
| Intangible assets | InterimInstant | 9153000000 | JPY |
| Investment securities | Prior1YearInstant | 12327000000 | JPY |
| Investment securities | InterimInstant | 17786000000 | JPY |
| Deferred tax assets | Prior1YearInstant | 2312000000 | JPY |
| Deferred tax assets | InterimInstant | 2293000000 | JPY |
| Other ioa | Prior1YearInstant | 2162000000 | JPY |
| Other ioa | InterimInstant | 2464000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -17000000 | JPY |
| Allowance for doubtful accounts ioa by group | InterimInstant | -17000000 | JPY |
| Investments and other assets | Prior1YearInstant | 16784000000 | JPY |
| Investments and other assets | InterimInstant | 22526000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 45881000000 | JPY |
| Noncurrent assets | InterimInstant | 50948000000 | JPY |
| Assets | Prior1YearInstant | 103889000000 | JPY |
| Assets | InterimInstant | 108773000000 | JPY |
| Accounts payable trade | Prior1YearInstant | 6411000000 | JPY |
| Accounts payable trade | InterimInstant | 7679000000 | JPY |
| Electronically recorded obligations operating cl | Prior1YearInstant | 2735000000 | JPY |
| Electronically recorded obligations operating cl | InterimInstant | 1859000000 | JPY |
| Short term loans payable | Prior1YearInstant | 4461000000 | JPY |
| Short term loans payable | InterimInstant | 3702000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 1210000000 | JPY |
| Provision for bonuses | InterimInstant | 1239000000 | JPY |
| Other provision cl | Prior1YearInstant | 73000000 | JPY |
| Other provision cl | InterimInstant | － | JPY |
| Other cl | Prior1YearInstant | 7985000000 | JPY |
| Other cl | InterimInstant | 8915000000 | JPY |
| Current liabilities | Prior1YearInstant | 22879000000 | JPY |
| Current liabilities | InterimInstant | 23397000000 | JPY |
| Long term loans payable | Prior1YearInstant | 6441000000 | JPY |
| Long term loans payable | InterimInstant | 8932000000 | JPY |
| Other ncl | Prior1YearInstant | 3011000000 | JPY |
| Other ncl | InterimInstant | 3849000000 | JPY |
| Noncurrent liabilities | Prior1YearInstant | 9453000000 | JPY |
| Noncurrent liabilities | InterimInstant | 12781000000 | JPY |
| Liabilities | Prior1YearInstant | 32333000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |